Cannabinoid Therapy Cuts Pain and Improves Outcomes in Prostate Cancer: 90-Man Study

A new peer-reviewed study published in April 2026 in the journal Medical Cannabis and Cannabinoids reports that cannabinoid therapy — whether used on its own or alongside conventional chemotherapy — was associated with reduced pain, improved quality of life, and early signs of tumour response in men with confirmed prostate cancer. The findings, drawn from a six-month prospective study of 90 patients, add to the growing clinical literature supporting a defined role for medical cannabis in oncology care.

The paper is the product of a collaboration between researchers at South Africa's Tshwane University of Technology, Durban University of Technology, and Canada's University of Alberta. It is one of the most closely watched cannabinoid-oncology studies of the year because it measured both patient-reported outcomes and objective biological markers, and because it stratified participants into three distinct treatment arms.

How the Study Was Designed

Researchers followed 90 men with a histologically confirmed prostate cancer diagnosis over a six-month period. Participants were allocated to one of three groups:

• Chemotherapy alone — standard oncology care with no cannabis
• Cannabinoid therapy alone — cannabis-based medicine without concurrent chemotherapy
• Combination therapy — chemotherapy plus cannabinoids as an adjunct

Assessments were performed at baseline, three months, and six months. The research team tracked:

• Prostate-specific antigen (PSA) levels, a standard biomarker of prostate cancer activity
• PET/CT imaging to assess tumour metabolic activity and disease progression
• Brief Pain Inventory (BPI) scores, a validated patient-reported pain measure
• EuroQol EQ-5D quality-of-life index

Longitudinal change across each endpoint was analyzed using linear mixed-effects regression, an approach that accounts for individual baseline variation and repeated measurements.

What the Researchers Found

Across the six-month observation window, the cannabinoid and combination groups reported clinically meaningful reductions in pain severity and pain interference compared with the chemotherapy-only arm. Quality-of-life indexes also improved more substantially in the cannabis-exposed groups.

On the biological side, the authors reported:

• PSA levels trended more favorably in the combination arm than in chemotherapy alone
• PET/CT imaging showed metabolic activity consistent with tumour response in a subset of cannabinoid-treated patients
• No evidence of harm or clinically significant adverse interaction between cannabinoids and chemotherapy was recorded

The authors concluded that "cannabinoid therapy, whether used independently or alongside chemotherapy, was associated with improved pain control and some indicators of tumour response, without evidence of harm" — language that is deliberately restrained but marks a clear signal for further investigation.

Why These Findings Matter for Cancer Care

Cancer pain is one of the most common and least adequately managed symptoms in oncology. In the United States, roughly 1 in 8 men will be diagnosed with prostate cancer in their lifetime, and up to 70% of advanced cancer patients report pain that is moderate to severe. Opioid analgesics remain the standard of care, but carry risks of tolerance, dependence, and side effects that impair quality of life.

Prior evidence on cannabis for cancer pain has been mixed. A 2023 Cochrane systematic review found that cannabis-based medicines may modestly reduce cancer-related pain but noted most trials were small and of short duration. A 2024 BMJ Group review reported medicinal cannabis was safe and appeared to reduce total medication use in cancer patients. A 2025 Frontiers in Oncology meta-analysis of cannabis and cancer outcomes pointed to symptom-control benefits with inconclusive data on disease modification.

The new prostate-specific study adds three pieces that were largely missing from the prior record:

1. Prospective six-month design with both patient-reported outcomes and objective tumour markers in the same patients.
2. Three-arm stratification that separates the contribution of cannabinoids as monotherapy from their contribution as an adjuvant to chemotherapy.
3. Signal of biological activity in PSA and PET/CT data, not just symptom relief.

It is important to emphasize what the study does not establish. It is not a randomized controlled trial, the sample size is modest, and the patient population was drawn from specific clinical sites. The authors themselves call for "further randomized studies to clarify cannabinoids' adjunctive role in prostate cancer management." Clinicians and patients should interpret the results as a promising signal, not a treatment recommendation.

How Cannabinoids May Act Against Prostate Cancer

The mechanistic rationale for the study is grounded in a decade of preclinical work. Prostate cancer cells express CB1 and CB2 cannabinoid receptors, and in laboratory and animal models:

• THC and CBD have been shown to induce apoptosis (programmed cell death) in prostate cancer cell lines
• Cannabidiol (CBD) has inhibited proliferation and invasiveness of prostate cancer cells in vitro
• Cannabinoid receptor agonism has been linked to reduced angiogenesis — the formation of new blood vessels tumours need to grow

On the symptom-management side, THC and CBD act on pain pathways both centrally and peripherally, and their anti-inflammatory and anti-emetic effects help manage chemotherapy side effects. The entourage effect, in which THC, CBD, and terpenes modulate each other's activity, has been proposed as an explanation for why whole-plant preparations can outperform single-molecule drugs in some pain endpoints.

Population-level data have also hinted at a relationship between cannabis use and prostate cancer risk. A 2024 National Survey on Drug Use and Health analysis found cannabis use was associated with a reduced prevalence of prostate cancer — an association that does not prove causation but is consistent with the biological hypothesis that cannabinoids may exert an antitumour effect.

What Patients and Physicians Should Take Away

For patients already being treated for prostate cancer, the study does not change standard-of-care recommendations. Chemotherapy, hormone therapy, radiation, and surgery remain the evidence-based pillars of treatment. Patients considering medical cannabis should have an explicit conversation with their oncology team, because:

• Cannabinoids can interact with some chemotherapy agents through the cytochrome P450 metabolic pathway
• Product consistency matters — dosing, cannabinoid ratios, and contaminant testing vary by supplier
• State medical cannabis programs differ in what conditions qualify and what products are available

For oncologists and health systems, the study strengthens the case for routinely asking patients about cannabis use, documenting it in the medical record, and pursuing formal institutional review of cannabinoid-adjunct protocols. Several academic medical centers, including UCSD's Center for Medicinal Cannabis Research and UC-affiliated cannabis clinical trial networks, are already running prospective studies in related cancer populations.

For policymakers, it strengthens the argument for rescheduling cannabis from Schedule I to Schedule III, which would dramatically reduce the regulatory burden on federally funded cannabis cancer research.

Key Takeaways

• A six-month, 90-patient study published April 2026 in Medical Cannabis and Cannabinoids found cannabinoid therapy was associated with reduced pain and improved quality of life in men with prostate cancer.
• The combination of chemotherapy plus cannabinoids showed favorable PSA trends and early PET/CT signs of tumour response compared with chemotherapy alone.
• No evidence of harm was recorded, but the authors caution that larger randomized trials are required before the findings can change clinical practice.
• Prior lab and population data support a biological rationale for cannabinoid activity against prostate cancer cells.
• Patients interested in medical cannabis during oncology care should always coordinate with their treating physician to manage drug interactions and product selection.

Explore cannabis research, find dispensaries, and join the community at Budpedia.